pharma-congress-molecular-medicine-2018-tracks

9 / 10

Page 28
Note:
O c t o b e r 1 9 - 2 0 , 2 0 1 8 | T o k y o , J a p a n
Pharma Congress 2018 & Molecular Medicine 2018
& Psychiatric Disorders 2018 Asian Journal of Biomedical and Pharmaceutical Sciences | ISSN: 2249-622X| Volume 8
International Conference on
PHARMACEUTICS AND NOVEL DRUG DELIVERY SYSTEMS
19th International Conference on
CELLULAR AND MOLECULAR MEDICINE
19th Annual Congress on
PSYCHIATRY AND PSYCHIATRIC DISORDERS
&
&
OF EXCELLENCE
IN INTERNATIONAL
MEETINGS
YEARS
Baranov V S Yarmolinskaya M I, Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C3-008
DEVELOPMENTAL GENETICS OF
ENDOMETRIOSIS
Baranov V S Yarmolinskaya M I
Ott’s Institute of Obstetrics, Gynecology and Reproductology, Russian Federation
Over 100 years the problem of endometriosis (EM) a common disabilitat-
ing female disease remains very urgent with no efficient prevention, pre-
diction or treatment known so far. For many decades EM was in the focus
of complex studies in our institute. The report highlights major advances in
molecular genetic studies of endometriosis, its pathogenomics, as well as
some recent hypothesis in this area. Spectacular progress in this area could
be attributed to the systems genetic view of EM which implies identification
of many (over 100) EM genes, analysis of their functional allelic variants,
comparative gene expression studies in euthopic and ectopic endometrium,
gene interactions within relevant (about 30) metabolic pathways, as well as
complex epigenetic damages due to abnormal methylation pattern and miR-
NA deregulation. Endometrial stem cells (eSC) which reside in the borderline
of endometrium and myometrium l within junction layer (eSC niche), or mes-
enchymal stem cells - the products of epithelial/mesenchymal cells transition
(EMT) was shown play a major role in the origin of endometriosis. Also, the
peculiarities of personal genetic background, unique “epigenetic landscape”
of genetically and epigenetically predisposed to EM stem cells underlie the
origin of pathological process which soon becomes canalized and irrevers-
ible and proceeds to final clinical manifestation. Novel data on the molecular,
genetic and epigenetic mechanisms governing EM suggests the existence of
endometriosis development genetic program (EMDP) mitigated with at least
three tentative r sensitive periods (SP). The origin of genetically or epigeneti-
cally modified stem cells potentially destined to give rise to endometriosis
(SP1), endometrial epithelium cells transition (metaplasia) into mesenchymal
SCs through EMT) (SP2), and their invasion into peritoneum with subsequent
progression into endometriotic lesions (SP3). Feasible origin of EM from
the embryonic stem cells disseminated throughout the pelvic lining during
female urogenital system embryogenesis should not be considered as well.
Complex genomic and epigenetic interactions at different stages of EMs pro-
gression result in different forms of the disease, with their specific traits and
clinical manifestations. The EMDP and especially its highly vulnerable sensi-
tive periods might be of major significance in elaboration a new strategy of
EM prediction, prevention, and treatment.
Baranov V S Yarmolinskaya M I Born in 1940, graduat-
ed from the State Medical Institute in Lvov (Ukraina),
took postgraduate courses and received a PhD degree
in Saint-Petersburg (Russia) in 1976 . The Chief of
laboratory for prenatal diagnosis of inherited and inborn
diseases at the Ott’s Institute of Obstetrics, Gynecology
& Reproduction. Interested in genetic and cytogenetic
aspects of early development, gene testing of inherited
predisposition to common disorders , personalized pre-
dictive medicine, gene therapy. Professor, Correspond-
ing Member of Russian Academy of Sciences, Hon-
orary Scientist, Chief City Expert in Medical Genetics, ,
The author and co-author of 29 books and over 400
scientific papers.
BIOGRAPHY